Business Wire

HCL Technologies Launches a Global Hackathon to Identify Long-Term Technology Solutions to the COVID-19 Pandemic

20.8.2020 15:00:00 EEST | Business Wire | Press release

Share

HCL Technologies , (HCL), a leading global technology company, today announced a multi-phase hackathon, “Better Health Hackathon: #CodeforCOVID19,” to crowdsource technology innovation to find solutions for the immediate and long-term societal impact of the COVID-19 pandemic, including pandemic containment and prevention; diagnosis, treatment and therapeutic management; recovery and return to normal; and systemic solutions for future crises.

As part of the program, HCL has partnered with Microsoft and International SOS, the world's largest medical and travel security services firm, who are providing business and technical oversight to the contest and feedback to team entries. In addition, the Better Health Hackathon is bringing together a wide-ranging and prestigious group of executives and companies, across multiple industries, to serve as judges and advisory panel members. This includes scholars from Johns Hopkins University, University of Cambridge, Tuck School of Business, The University of Queensland, Indian Institute of Technology, Kanpur, and subject matter experts from HCL.

The competition is open to technology innovators, entrepreneurs and problem solvers from the global developer community. To date the Better Health Hackathon has received more than 7500 registrations from 600+ unique organizations and academic institutions spanning 350 locations across 52 countries. To engage top talent in the coding community, the Hackathon is partnering with BeMyApp to leverage their expansive network of coders and tech enthusiasts. The Hackathon is open to eligible participants who are at least 18 years of age.

“The unique capabilities and strength of HCL’s global ecosystem of partners, coupled with the immense talent and best minds from the tech, developer and entrepreneur communities, enables us to make a significant contribution during the COVID-19 pandemic,” said Arthur Filip, Executive Vice President, Sales Transformation & Marketing, HCL Technologies. “Technology has a big role to play in alleviating the challenges brought on by the pandemic, addressing solutions for successful containment and the reorientation of business and society. We are honored to curate a very enthusiastic, committed and deeply talented global community to help us in this important work.”

Neeraj Balani, Managing Director, International SOS, India, said, “We are honored to be part of this initiative with our customer, HCL Technologies, and are confident that the outcomes will provide breakthroughs and benefits for employee health and wellness, which ultimately has a large impact on empowering business resilience, continuity and sustainability.”

Takuya Hirano, VP, Partner Services, Microsoft Corp., said, “This hackathon presents an opportunity for technology experts and innovative thinkers to showcase how advanced technology can help identify solutions to challenging problems facing societies. Technology can serve as a vehicle to drive new solutions that help improve the wellbeing of our communities and prepare us for future health challenges.”

Specifically, the HCL Better Health Hackathon: #CodeforCOVID19 will address the following areas:

  • Prevention and containment: #StayAtHome
    • This track explores solutions that better safeguard the most vulnerable in our communities, better communicate credible information, and help people better cope with the challenges of self-isolation. This track will examine: How can technology aid efforts to #FlattenTheCurve by offering a better quality of life to encourage people to #StayAtHome.
  • Diagnosis, treatment & therapeutic management
    • This track focuses on ways to help better protect and equip frontline healthcare workers and first responders, and to better serve those individuals and organizations seeking treatments and cures for COVID-19 with technology solutions.
  • Recovery and return to normal
    • This track dives into the next phase of society after shutdown orders are removed. In the absence of a tested and available vaccine or therapeutic treatments against COVID-19, how can technology safeguard communities against a relapse of an outbreak, once social distancing and other restrictions are lifted throughout the world, allowing people to return to public spaces.
  • Systemic solutions for crises and pandemic management
    • This track ideates innovative uses for next-gen technologies to plan for the long-term implications of COVID-19 and better prepare for future global pandemic-related challenges across healthcare and public services ecosystems.

About HCL Technologies

HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL’s Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.

HCL offers its services and products through three business units - IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.

As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2020, HCL has a consolidated revenue of US $ 9.93 billion and its 150,287 ideapreneurs operate out of 49 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further details, please contact:
HCL Technologies

Anne Coyle, US
Anne.coyle@hcl.com

Elka Ghudial, Europe
Elka.ghudial@hcl.com

Devneeta Pahuja, India and APAC
Devneeta.p@hcl.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye